Daily Health Headlines

FDA OKs 1st Drug to Treat Duchenne Muscular Dystrophy

👤by Mary Elizabeth Dallas 0 comments 🕔Wednesday, September 21st, 2016

Exondys 51 (eteplirsen) was granted accelerated approval to treat Duchenne muscular dystrophy, a genetic disorder that progressively weakens the muscular systems of its victims. Most are in a wheelchair by their teens and do not survive past their 20s or 30s.

"Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"In rare diseases, new drug development is especially challenging, due to the small numbers of people affected by each disease and the lack of medical understanding of many disorders," Woodcock said.

"Accelerated approval makes this drug available to patients based on initial data, but we eagerly await learning more about the efficacy [effectiveness] of this drug through a confirmatory clinical trial that the [drug's maker] must conduct after approval," Woodcock added.

The FDA gave its accelerated approval even though an agency advisory panel had recommended against the drug, saying there was little evidence that it benefited patients. That advisory vote was met with significant pushback from patients' families, some physicians and politicians, the Associated Press reported.

Under the accelerated approval provision, the FDA is requiring the maker of Exondys 51 -- Sarepta Therapeutics of Cambridge, Mass. -- to conduct a clinical trial to confirm that the drug helps patients.

Duchenne is the most common form of muscular dystrophy. The disease occurs when the body lacks a protein, called dystrophin, that helps keep muscle cells intact.

Exondys 51, which is injected, is specifically used for the treatment of patients who have a confirmed mutation in the gene that produces dystrophin, the FDA said.

Essentially, the drug helps cells "skip" over the faulty section of genetic coding and allows the production of a form of the dystrophin protein, according to Sarepta Therapeutics.

Exondys 51 was placed on a fast-track approval, which speeds up the review of drugs that are intended to treat serious or life-threatening conditions or have the potential to address an unmet medical need. This approval can be based on research that shows there is a reasonable likelihood that the drug will benefit patients, the FDA said.

Exondys 51 was also given an "orphan drug" designation, which provides certain financial incentives to drug makers to encourage the development of drugs for rare diseases.

The accelerated approval was based on findings that the drug helped increase skeletal muscle in some patients, the FDA said.

Commonly reported side effects among those taking Exondys 51 included balance disorder and vomiting. The FDA said its decision to grant preliminary approval to the drug takes into account that Duchenne is a life-threatening and debilitating disease affecting children.

Disease symptoms usually develop early in life, between the ages of 3 and 5, and become more severe with age. People lose the ability to perform normal daily tasks without help. Many patients must use a wheelchair by the time they are teenagers. Over time, potentially fatal heart and lung conditions can develop.

Boys develop Duchenne far more often than girls. But, the disease can affect anyone -- even those who don't have a family history of the genetic disorder, the FDA said. Roughly one of every 3,600 male infants worldwide has the disease.

-- Mary Elizabeth Dallas

Article Credits / Source

Mary Elizabeth Dallas / HealthDay

Mary Elizabeth Dallas wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCE: U.S. Food and Drug Administration, news release, Sept. 19, 2016; Associated Press

View More Articles From Mary Elizabeth Dallas 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Daily Health & Medical News Articles

U.S. Death Toll From Infectious Diseases Unchanged: Study

U.S. Death Toll From Infectious Diseases Unchanged: Study0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- The war against infectious diseases -- medicine versus microbes -- has been holding steady, with the U.S. death rate from these diseases about the same now as it was in 1980, new research says. But ...

2 Doses of HPV Vaccine Effective for Younger Teens

2 Doses of HPV Vaccine Effective for Younger Teens0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- New global research confirms that two doses of the vaccine for HPV, rather than three, can protect younger teens against the sexually transmitted virus. Based on this study and others, U.S. government ...

Tobacco Flavors Draw in Young Folks

Tobacco Flavors Draw in Young Folks0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- Flavored tobacco products attract young people who also consider them less harmful, researchers say. The University of North Carolina team reviewed 40 studies conducted in the United States and other ...

Health Tip: Exercise Can Be a Brain-Booster

Health Tip: Exercise Can Be a Brain-Booster0

(HealthDay News) -- Exercise does more than keep your body healthier. It also affects chemicals in your brain that help you think and focus. The American Council on Exercise says: Exercise improves alertness and focus, and helps you feel ...

New Fetal Views in 3-D

New Fetal Views in 3-D0

MONDAY, Nov. 21, 2016 (HealthDay News) -- Expectant parents may soon be able to view a three-dimensional virtual reality version of the fetus, researchers say. This is possible with new technology that combines MRI and ultrasound data into a ...

View More Daily Health & Medical News Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!